Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
BACKGROUND
The optimal rasburicase dose for adult patients has not been determined.


OBJECTIVE
To retrospectively examine use of rasburicase in our centre and to evaluate the effect of a single dose of rasburicase on urate and serum creatinine levels in our adult patients.


METHODS
A retrospective chart review was conducted of all adult patients who received rasburicase for treatment of tumour lysis syndrome-associated hyperuricaemia at our academic, urban medical centre from July 2002 to October 2006.


RESULTS
Twenty-one patients received rasburicase with an average first dose of 0.15 +/- 0.03 mg/kg. The drug dosing was calculated based on the patients' ideal body weight (IBW) or adjusted body weight (aBW) for those who were more than 30% above their IBW. Patients experienced a mean serum urate reduction of 89.7 +/- 9.0% from the baseline through the first 24 h after a single rasburicase dose (11.4 +/- 4.5 mg/dL vs. 1.4 +/- 1.4 mg/dL, respectively, P < 0.001). The urate levels remained within normal limits (<8 mg/dL) in all the patients for 48 h after a single dose of rasburicase. The major limitation of our study is that in 18 of 21 patients we lacked adequate documentation to ascertain that the blood samples sent for urate analysis after drug administration were handled according to the manufacturer's recommendations. However, in this small group of patients, we observed that the effect of rasburicase on serum urate was similar to the total study population. The effect was sustained for 48 h after a single dose. Serum creatinine levels at 24-72 h after the single rasburicase dose were not significantly different from baseline (1.8 mg/dL vs. 2.3 mg/dL, respectively, P = 0.14).


CONCLUSIONS
Rasburicase is an effective treatment for patients with hyperuricaemia and may aid in the prevention of hyperuricaemia-associated nephrotoxicity. From our experience, a single dose of 0.15 mg/kg (IBW or aBW) of rasburicase appears to effectively decrease and maintain urate levels within normal limits for 48 h.
Campara
M
M
Department of Pharmacy Practice, University of Illinois, Chicago, IL, USA.
Shord
S S
SS
Haaf
C M
CM
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D016527:Drug Costs; D005260:Female; D006074:Gout Suppressants / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000191:economics; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D012189:Retrospective Studies; D015275:Tumor Lysis Syndrome / Q000188:drug therapy* / Q000191:economics; D014503:Urate Oxidase / Q000191:economics / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood
D000970:Antineoplastic Agents; D006074:Gout Suppressants; C469709:rasburicase; D014527:Uric Acid; D003404:Creatinine; D014503:Urate Oxidase